Germinal center-induced cross-protective immunity. A, Experimental design. Three macaques were challenged with 12.5mL of SARS-CoV-2 virus (2.1×106 TCID50/mL, S clade). After the ASCs from the primary infection had disappeared from all infected macaques, 3 infected macaques were rechallenged at 124 dpi with the SARS-CoV-2 GH clade. Additionally, 3 uninfected monkeys (controls) were challenged at 0 dpi with the same SARS-CoV-2 (GH clade) as that used to reinfect animals. B, IgM and IgG antibody responses specific for SARS-CoV-2 spike (S1+S2) proteins were analyzed using plasma collected at 0, 1, 7, 14, 21, 28, 56, 112, and 124 dpi following the initial infection, using the ELISA (1-way ANOVA with Dunnett test for multiple comparisons vs 0 dpi; ∗P<.05, ∗∗P<.01, ∗∗∗P<.001). C, Representative ELISPOT data of SARS-CoV-2 spike protein (S1+S2)-specific IgM (blue) and IgG (red) ASCs in peripheral blood mononuclear cells of primary-challenged primates. Circles represent individual data (1-way ANOVA with Dunnett test for multiple comparisons vs 0 dpi; ∗∗P<.01, ∗∗∗P<.001). D, Representative ELISPOT data of SARS-CoV-2 spike protein (S1+S2)-specific IgM (blue) and IgG (red)-secreting cells differentiated from MBCs over 4 days using anti-CD3 and anti-CD28 monoclonal antibodies (1 μg/mL). Circles represent individual data (1-way ANOVA with Dunnett test for multiple comparisons vs 0 dpi; ∗P<.05). E, After infection with the S and GH clade, neutralization indicated according to plasma dilution at 124 dpi. F, Virus titers of swab samples in which viral RNA (copies/mL) was quantified using qRT-PCR and TCID50/mL was determined. Circles represent individual data and bar values represent mean±SEM. Abbreviations: ANOVA, analysis of variance; ASC, antibody-secreting cell; CM, cynomolgus macaque; dpi, days postinfection; ELISA, enzyme-linked immunosorbent assay; ELISPOT, enzyme-linked immunospot; Ig, immunoglobulin; MBC, memory B cell; OD, optical density; qRT-PCR, quantitative reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TCID50, 50% tissue culture infectious dose.